Research programme: human monoclonal antibodies - GlaxoSmithKline/Medarex
Latest Information Update: 03 May 2007
At a glance
- Originator GlaxoSmithKline; Medarex
- Developer Medarex
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune disorders; Bacterial infections; Cancer
Most Recent Events
- 03 May 2007 Discontinued - Preclinical for Autoimmune disorders in USA (unspecified route)
- 03 May 2007 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
- 03 May 2007 Discontinued - Preclinical for Cancer in USA (unspecified route)